--- title: "Recent Updates for Patients: Lower Drug Prices Through Centralized Procurement, New Reimbursed Medicines, and Progress in China-Developed Cancer Drugs" url: "https://www.yyhmedical.com/en/news/patient-medical-news-roundup-2026" type: Article inLanguage: en-US category: Medical Advances datePublished: 2026-03-18 --- # Recent Updates for Patients: Lower Drug Prices Through Centralized Procurement, New Reimbursed Medicines, and Progress in China-Developed Cancer Drugs > A quick roundup of recent updates on centralized procurement, reimbursement, new medicines, and clinical research to help patients stay informed about treatment developments. Summary: Several recent policy and treatment updates may be especially relevant to patients with blood disorders and cancer. These include lower prices for some platelet-boosting medicines following national centralized procurement, implementation of the updated National Reimbursement Drug List, the addition of several innovative lung cancer medicines to reimbursement coverage, and new clinical data for a China-developed HER2-targeting ADC. These developments may help ease medication costs while expanding treatment options. This article summarizes recent policy, drug, and clinical research updates to help patients and families stay informed and support informed discussions with their healthcare teams. As “BoYi Tongxing,” a dedicated community for patients with blood disorders and cancer, we closely follow the issues that matter most to patients. We have recently gathered several practical updates—from lower drug prices under centralized procurement and new clinical data for important cancer therapies to personal income tax relief related to major medical expenses. We hope these updates provide timely and useful information for patients and families. **Centralized Procurement Takes Effect, Lowering Prices of Platelet-Boosting Medicines** Platelet-boosting medicines are essential for many patients with leukemia, but their cost has placed significant pressure on some families. In February 2026, the 11th round of China’s national centralized drug procurement took effect. Across 55 medicines, prices fell by an average of 57%, while six products—including avatrombopag tablets—saw price reductions of more than 98%. Prices for several platelet-boosting medicines have already been adjusted in provinces including Gansu and Hebei, and some patients have received prescriptions at the new procurement prices. Patients can check with their hospital or doctor, or consult official local channels, to confirm whether the policy has been implemented in their area. ![1b396bc6-6f4e-4b14-9661-41a89920c473.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/6b3615e7d03478bfad4a8b4259a08d24_20260914020218.png "6b3615e7d03478bfad4a8b4259a08d24_20260914020218.png") **More Lung Cancer Medicines Added to Reimbursement Coverage and Available at Shanghai GoBroad Cancer Hospital** China’s updated National Reimbursement Drug List (NRDL) took effect on January 1, 2026, adding 114 medicines, including 37 anticancer drugs. Several medicines for lung cancer are now included in reimbursement coverage and can be prescribed at Shanghai GoBroad Cancer Hospital. Key information is summarized below: **Trastuzumab Rezetecan for Injection** ◆ Eligible patients: Adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a HER2 (ERBB2) activating mutation who have received at least one prior systemic therapy. ◆ Drug type: Antibody-drug conjugate (ADC). **Garsorasib Tablets** ◆ Eligible patients: Adults with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. ◆ Drug type: Targeted therapy. **Pralsetinib Capsules** ◆ Eligible patients: Adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC). ◆ Drug type: Targeted therapy. **Selpercatinib Capsules** ◆ Eligible patients: Adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC). ◆ Drug type: Targeted therapy. **Taletrectinib Adipate Capsules** ◆ Eligible patients: Adults with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). ◆ Drug type: Targeted therapy. **Fulzerasib Tablets** ◆ Eligible patients: Adults with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. ◆ Drug type: Targeted therapy. **New Clinical Data for a China-Developed Cancer Drug Bring New Treatment Potential for Gastrointestinal Cancers** Phase I clinical data have been published for trastuzumab rezetecan, a China-developed HER2-targeting antibody-drug conjugate (ADC), in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ) and colorectal cancer (CRC). The findings were published in the Journal of Clinical Oncology (JCO; impact factor: 43.4). Professor Jin Li, President of Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, served as the corresponding author. The early-phase results showed promising antitumor activity and safety findings in patients with HER2-expressing GC/GEJ and CRC. A Phase III study of trastuzumab rezetecan as second-line treatment for GC/GEJ (NCT06123494) is currently underway. In addition, the application for a new indication in colorectal cancer has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration and granted priority review. ![332139e6-1100-4ad7-8d6a-e9b5e0bfdc72.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/224fcd928cd42b9a667a70c99967f33b_20260914020256.png "224fcd928cd42b9a667a70c99967f33b_20260914020256.png") Study Published in JCO --- Original (HTML):https://www.yyhmedical.com/en/news/patient-medical-news-roundup-2026 This is a clean Markdown mirror for large language models; the original page is authoritative.